1
-
3
of
3
results (0.69 seconds)
Sort By:
-
Biosimilars, Part 6: Maximizing Adoption
com/content/dam/corp/web/documents/Report/cardinal-health-2022-biosimilars-report.pdf. So, most clinicians are ... com/content/dam/corp/web/documents/Report/cardinal-health-2022-biosimilars-report.pdf. In oncology, we see a ...- Authors: Tony Pistilli, Greg Warren
- Date: Jan 2024
- Competency: External Forces & Industry Knowledge
- Publication Name: Health Watch
- Topics: Health & Disability
-
Biosimilars, Part 3: Humira Biosimilar Launches
has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world ... has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is ...- Authors: Tony Pistilli, Greg Warren
- Date: Nov 2023
- Competency: External Forces & Industry Knowledge; Strategic Insight and Integration
- Publication Name: Health Watch
- Topics: Health & Disability; Health & Disability>Health care; Health & Disability>Health insurance; Public Policy; Public Policy; Public Policy
-
Biosimilars, Part 4: The Financial Impact
Amgen’s analysis of market data in their Biosimilar Report (see page 15). Biosimilar Uptake Pace is Critical ... resulting from biosimilars (see Amgen Biosimilar Report, page 14). The oldest biosimilar (Filgrastim), ...- Authors: Greg Warren, Tony Pistilli
- Date: Nov 2023
- Competency: External Forces & Industry Knowledge; Strategic Insight and Integration
- Publication Name: Health Watch
- Topics: Health & Disability; Health & Disability>Health care; Health & Disability>Health insurance; Public Policy; Public Policy; Public Policy